Series B · Medtech & Devices · Dublin, Ireland · Founded 2016 · 11–50 employees
CroíValve develops the DUO System, a minimally invasive transcatheter device to treat tricuspid regurgitation (TR), a severe cardiac condition affecting over 4 million people in the US and Europe. The device seals gaps between native valve leaflets through the heart's blood vessels, avoiding the need for risky open-heart surgery in elderly patients. The company has raised over $40M in funding including a recent $16M Series B round in 2024, and has received FDA approval to begin a US feasibility study. CroíValve is a Trinity College Dublin spin-out founded by leading medical experts in the field.